Bibliography
- Montecucco F, Quercioli A, Mach F. Ezetimibe/simvastatin. Expert Opin Drug Saf 2009;8:715-25
- Grundy SM, Cleeman JI, Merz CN, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-32
- Taylor AJ, Villines TC, Stanek EJ, Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22
- Kastelein JJ, Akdim F, Stroes ES, Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43
- Gordon DJ, Probstfield JL, Garrison RJ, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
- Briel M, Ferreira-Gonzalez I, You JJ, Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338:b92
- Mathur A, Walker JJ, Al-Azzawi HH, Ezetimibe ameliorates cholecystosteatosis. Surgery 2007;142:228-33
- Wang HH, Portincasa P, Mendez-Sanchez N, Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 2008;134:2101-10
- Fleg JL, Mete M, Howard BV, Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in Type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008;52:2198-205
- Meaney A, Ceballos G, Asbun J, The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol 2009;49:838-47
- Landray M, Baigent C, Leaper C, The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 2006;47:385-95
- Targher G, Bertolini L, Padovani R, Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled Type 2 diabetic patients. J Endocrinol Invest 2006;29:55-60
- Targher G, Bertolini L, Rodella S, Non-alcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in Type 2 diabetic patients. Diabetes Care 2007;30:2119-21
- Zheng S, Hoos L, Cook J, Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 2008;584:118-24
- Deushi M, Nomura M, Kawakami A, Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007;581:5664-70
- Nomura M, Ishii H, Kawakami A, Yoshida M. Inhibition of hepatic neiman-pick C1-like 1 improves hepatic insulin resistance. Am J Physiol Endocrinol Metab 2009. [Epub ahead of print]
- Buchanan C, Smith L, Corbett J, A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 2006;6:770-4
- Alsheikh-Ali AA, Karas RH. Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: a post-marketing analysis. J Clin Lipidol 2009;3(2):138-42
- Peto R, Emberson J, Landray M, Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008;359:1357-66